Alembic Pharmaceuticals Limited (APLLTD.BO)
INR 850.0
(0.7%)
INR 850.0
(0.7%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 15.86 Billion INR | -29.41% |
| 2022 | 30.22 Billion INR | 3.67% |
| 2021 | 29.15 Billion INR | 18.61% |
| 2020 | 24.58 Billion INR | 18.93% |
| 2019 | 20.66 Billion INR | 11.16% |
| 2018 | 18.59 Billion INR | 27.09% |
| 2017 | 14.63 Billion INR | -0.57% |
| 2016 | 14.71 Billion INR | 26.62% |
| 2015 | 11.62 Billion INR | 29.33% |
| 2014 | 8.98 Billion INR | 21.43% |
| 2013 | 7.39 Billion INR | 31.41% |
| 2012 | 5.63 Billion INR | 14.28% |
| 2011 | 4.92 Billion INR | 2.64% |
| 2010 | 4.8 Billion INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.51 Billion INR | 15.84% |
| 2023 Q2 | 9.92 Billion INR | 5.6% |
| 2023 FY | 21.33 Billion INR | -29.41% |
| 2023 Q1 | 9.4 Billion INR | 170.37% |
| 2023 Q3 | 9.72 Billion INR | -2.01% |
| 2023 Q4 | 4.75 Billion INR | -51.1% |
| 2022 Q2 | 8.66 Billion INR | -7.41% |
| 2022 FY | 30.22 Billion INR | 3.67% |
| 2022 Q3 | 8.71 Billion INR | 0.56% |
| 2022 Q4 | 3.47 Billion INR | -60.11% |
| 2022 Q1 | 9.36 Billion INR | 39.39% |
| 2021 FY | 29.15 Billion INR | 18.61% |
| 2021 Q2 | 7.75 Billion INR | 1.99% |
| 2021 Q1 | 7.6 Billion INR | 104.57% |
| 2021 Q3 | 7.43 Billion INR | -4.16% |
| 2021 Q4 | 6.71 Billion INR | -9.62% |
| 2020 FY | 24.58 Billion INR | 18.93% |
| 2020 Q4 | 3.71 Billion INR | -47.15% |
| 2020 Q3 | 7.03 Billion INR | -5.66% |
| 2020 Q2 | 7.45 Billion INR | 16.9% |
| 2020 Q1 | 6.37 Billion INR | 183.05% |
| 2019 Q1 | 5.55 Billion INR | 136.88% |
| 2019 FY | 20.66 Billion INR | 11.16% |
| 2019 Q4 | 2.25 Billion INR | -64.09% |
| 2019 Q2 | 6.58 Billion INR | 18.68% |
| 2019 Q3 | 6.27 Billion INR | -4.75% |
| 2018 Q4 | 2.34 Billion INR | -57.9% |
| 2018 Q1 | 4.83 Billion INR | 8.0% |
| 2018 Q2 | 5.81 Billion INR | 20.18% |
| 2018 Q3 | 5.56 Billion INR | -4.26% |
| 2018 FY | 18.59 Billion INR | 27.09% |
| 2017 Q2 | 4.22 Billion INR | 9.28% |
| 2017 FY | 14.63 Billion INR | -0.57% |
| 2017 Q4 | 4.47 Billion INR | -1.02% |
| 2017 Q3 | 4.52 Billion INR | 7.1% |
| 2017 Q1 | 3.86 Billion INR | -9.58% |
| 2016 Q1 | 4.05 Billion INR | 8.31% |
| 2016 FY | 14.71 Billion INR | 26.62% |
| 2016 Q3 | 4.45 Billion INR | -4.52% |
| 2016 Q4 | 4.27 Billion INR | -3.92% |
| 2016 Q2 | 4.66 Billion INR | 14.92% |
| 2015 Q3 | 3.47 Billion INR | -16.29% |
| 2015 Q1 | 2.77 Billion INR | 63.84% |
| 2015 Q4 | 3.74 Billion INR | 7.66% |
| 2015 FY | 11.62 Billion INR | 29.33% |
| 2015 Q2 | 4.15 Billion INR | 49.51% |
| 2014 Q4 | 1.69 Billion INR | -31.54% |
| 2014 Q3 | 2.47 Billion INR | -5.0% |
| 2014 Q2 | 2.6 Billion INR | 13.16% |
| 2014 Q1 | 2.3 Billion INR | 94.54% |
| 2014 FY | 8.98 Billion INR | 21.43% |
| 2013 Q2 | 2.11 Billion INR | 10.37% |
| 2013 Q1 | 1.92 Billion INR | 94.64% |
| 2013 Q3 | 2.16 Billion INR | 2.31% |
| 2013 FY | 7.39 Billion INR | 31.41% |
| 2013 Q4 | 1.18 Billion INR | -45.35% |
| 2012 FY | 5.63 Billion INR | 14.28% |
| 2012 Q3 | 1.61 Billion INR | 0.13% |
| 2012 Q4 | 986.43 Million INR | -38.78% |
| 2012 Q1 | 1.47 Billion INR | 0.0% |
| 2012 Q2 | 1.6 Billion INR | 9.12% |
| 2011 FY | 4.92 Billion INR | 2.64% |
| 2010 FY | 4.8 Billion INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Aurobindo Pharma Limited | 39.23 Billion INR | 59.552% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | -36.33% |
| Granules India Limited | 7.18 Billion INR | -120.954% |
| Indoco Remedies Limited | 4.74 Billion INR | -234.185% |
| Achyut Healthcare Limited | 1.6 Million INR | -986208.266% |
| Ajanta Pharma Limited | 30.46 Billion INR | 47.904% |
| Alkem Laboratories Limited | 32.83 Billion INR | 51.668% |
| Alpa Laboratories Limited | 156.14 Million INR | -10063.308% |
| Brooks Laboratories Limited | 51.18 Million INR | -30907.62% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | -510.279% |
| Bajaj HealthCare Limited | 985.34 Million INR | -1510.573% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -1018.197% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 83.448% |
| Eris Lifesciences Limited | 4.94 Billion INR | -221.058% |
| FDC Limited | 5.34 Billion INR | -196.711% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 76.512% |
| Gufic Biosciences Limited | 1.07 Billion INR | -1372.538% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -647.096% |
| Ipca Laboratories Limited | 13.91 Billion INR | -14.048% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -1951.913% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -34282.745% |
| Lasa Supergenerics Limited | 291.17 Million INR | -5350.246% |
| Laurus Labs Limited | 3.01 Billion INR | -427.092% |
| Lupin Limited | 95.67 Billion INR | 83.413% |
| Mankind Pharma Limited | 23.15 Billion INR | 31.457% |
| Medicamen Biotech Limited | 335.16 Million INR | -4634.864% |
| Medico Remedies Limited | 161.84 Million INR | -9705.553% |
| Megasoft Limited | 49.52 Million INR | -31941.876% |
| NATCO Pharma Limited | 10.05 Billion INR | -57.782% |
| Piramal Pharma Limited | 19.91 Billion INR | 20.309% |
| RPG Life Sciences Limited | 1.63 Billion INR | -870.327% |
| Sigachi Industries Limited | 579.88 Million INR | -2636.688% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 89.707% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -1031.296% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -1583.968% |
| Unichem Laboratories Limited | 6.72 Billion INR | -135.95% |
| Wanbury Limited | 1.16 Billion INR | -1266.985% |
| Windlas Biotech Limited | 1 Billion INR | -1476.706% |
| ZIM Laboratories Limited | 1.01 Billion INR | -1466.514% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 63.242% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | -415.786% |
| Divi's Laboratories Limited | 14.17 Billion INR | -11.995% |
| Hester Biosciences Limited | 908.84 Million INR | -1646.149% |
| Procter & Gamble Health Limited | 2.99 Billion INR | -429.802% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -1344.029% |
| Bal Pharma Limited | 389.89 Million INR | -3970.302% |
| Strides Pharma Science Limited | 9.16 Billion INR | -73.207% |
| Venus Remedies Limited | 1.91 Billion INR | -728.15% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | -416.189% |
| Nectar Lifesciences Limited | 625.55 Million INR | -2436.92% |
| Shilpa Medicare Limited | 2.18 Billion INR | -627.771% |
| Aarti Drugs Limited | 1.16 Billion INR | -1259.314% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -1344.276% |
| Suven Life Sciences Limited | 109.75 Million INR | -14359.863% |
| Ind-Swift Limited | 946.56 Million INR | -1576.553% |
| Valiant Laboratories Limited | 36.28 Million INR | -43631.434% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | -88.542% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | -246.523% |
| Themis Medicare Limited | 782.85 Million INR | -1927.157% |
| Hikal Limited | 2.48 Billion INR | -538.276% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 25.919% |
| Sequent Scientific Limited | 2.9 Billion INR | -446.89% |
| Novartis India Limited | 470.1 Million INR | -3275.814% |
| Wockhardt Limited | 6.4 Billion INR | -147.964% |
| Jubilant Pharmova Limited | 14.45 Billion INR | -9.795% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -97802.497% |
| Neuland Laboratories Limited | 2.92 Billion INR | -441.675% |
| Morepen Laboratories Limited | 1.98 Billion INR | -698.496% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -3747.881% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -2247.078% |